Isabelle Rosa
A5088831608- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Hepatocellular Carcinoma Treatment and Prognosis
- Inflammatory Bowel Disease
- Systemic Lupus Erythematosus Research
- Alcohol Consumption and Health Effects
- Gastrointestinal Bleeding Diagnosis and Treatment
- Diagnosis and treatment of tuberculosis
- Hepatitis Viruses Studies and Epidemiology
- HIV/AIDS drug development and treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Microscopic Colitis
- COVID-19 Clinical Research Studies
- Cannabis and Cannabinoid Research
- Blood groups and transfusion
- Gallbladder and Bile Duct Disorders
- Gastrointestinal disorders and treatments
- Eosinophilic Esophagitis
- Esophageal and GI Pathology
- Cytomegalovirus and herpesvirus research
- Genetic factors in colorectal cancer
- Diet, Metabolism, and Disease
Hôpital Intercommunal de Créteil
2016-2025
Centre Hospitalier Universitaire Henri-Mondor
2024
Hospital Universitario de Valme
2017
Université Paris-Est Créteil
2006-2014
Service de la Santé Publique
2014
Inserm
2010-2014
Agence Nationale de la Recherche
2014
Universitat de València
2013
Hôpital Jean-Verdier
2013
Vita-Salute San Raffaele University
2010
Aliment Pharmacol Ther 2011; 34: 656–663 Summary Background Transient elastography measures liver stiffness, which correlates with the hepatic fibrosis stage and has excellent accuracy for diagnosis of cirrhosis in patients chronic hepatitis C. Aim To assess prospectively kinetics stiffness treated C compare them viral on treatment final outcome therapy. Methods 91 significant (>7.0 kPa) at baseline were included. They received therapy pegylated interferon-α ribavirin. The characterized...
Background. With the advent of highly efficient antiviral therapies for hepatitis C virus (HCV) infection, providing broad access to diagnosis and care is needed. The dried blood spot (DBS) technique can be used collect, store, ship whole-blood specimens. Our goal was assess performance standardized HCV diagnostic monitoring tools in analysis DBS. Methods. Serum specimens collected using DBS from >500 patients were tested virological markers diagnose monitor infection. Results. Enzyme...
Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. Patients outside clinical trials seldom benefit from evidence‐based monitoring. The objective this study was to estimate cost‐effectiveness complying HCC screening guidelines. economic evaluation compared surveillance cirrhosis as recommended by guidelines (“gold‐standard monitoring”) “real‐life monitoring” health care system perspective. A Markov model described history disease and treatment course...
Background and AimsIn France, Bulevirtide (BLV) was available in September 2019 through an early access program to treat patients with hepatitis Delta virus (HDV). The aim of this analysis evaluate the efficacy safety BLV HIV HDV coinfection.Patients methodsPatients received 2 mg +/- pegylated interferon (pegIFNα) according physician's decision. primary endpoint (per-protocol analysis) virological response rate at week 48, defined as proportion undetectable serum HDV-RNA or decline > log10...
<b>Background and study aims:</b> The mortality rate from upper gastrointestinal bleeding (UGIB) remains high, at 5 % – 10 %. aim of the current was to describe epidemiological characteristics, prognostic factors, actual practice in a cohort patients with UGIB admitted French general hospitals. <b>Methods:</b> From March 2005 February 2006, prospective multicenter conducted 53 A total 3298 for were enrolled consecutively. Patient data collected up date discharge hospital. <b>Results:</b>...
Abstract Background & Aims Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious phase studies. Real‐world data daclatasvir+sofosbuvir GT infection are presented from the French Temporary Authorisation Use programme, which allowed patients need without other options access to daclatasvir ahead of its market authorization. Methods Patients with F3/F4 fibrosis and/or...
Recent data suggest that alcohol-related hepatocellular carcinoma (HCC) is diagnosed at a later stage. The aim of this study was to compare HCC characteristics and outcomes in an group (group A) non-alcohol-related NA).A total 1207 patients with newly were prospectively included between May 2008 October 2009. Patients multiple causes (alcohol plus another cause) excluded. followed every year for 5 years. Recorded variables, including etiologies tested as prognostic factors survival...
Summary Background Obeticholic acid (OCA) and fibrates are second‐line therapies for patients with primary biliary cholangitis (PBC) an inadequate response to ursodeoxycholic (UDCA). Aim To know whether OCA fibrates, administered together in combination UDCA, have additive beneficial effects difficult‐to‐treat PBC. Methods PBC treated ≥3 months (bezafibrate or fenofibrate) due failure of either therapy were included a multicentre, uncontrolled retrospective cohort study. Changes biochemical...
Because of the ongoing debate on benefit ultrasound (US) screening for hepatocellular carcinoma (HCC), we assessed impact hepatitis C virus (HCV)-related compensated cirrhosis patients aware their HCV status. A Markov model simulated progression from HCC diagnosis to death in 700 with HCV-related status estimate life expectancy (LE) and cumulative at 5 years. Five scenarios were compared: S1, no screening; S2, by currently existing practices (57% access effectiveness leading 42% Barcelona...
In France, 190,306 patients were suffering from chronic hepatitis C in 2012. These have a decreased life expectancy and are susceptible to complications associated with hepatitis. Current treatments poorly tolerated their effectiveness varies depending on the genotype of virus. Sofosbuvir, new class treatment, has demonstrated five phase III trials sustained viral response (SVR) rates over 90% across genotypes, higher than current tolerance profile similar placebo. The objective was...